# Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-vs-investigator-s-choice-in-recurrent-or-metastatic-squamous-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,J. Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Mark Lynch,Vijayvel Jayaprakash,Li Li,Maura L. Gillison |
| Citations | 808 |
| DOI | 10.1016/j.oraloncology.2018.04.008 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/6563923 |
| OpenAlex ID | https://openalex.org/W2799372507 |
| PMID | 29884413 |
| Type | article |
| Year | 2018 |

## Paper authors

- [George R. Blumenschein](https://scholariq.org/researchers/george-r-blumenschein/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.